The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial

Launched by THE GEORGE INSTITUTE · Jul 14, 2008

Keywords

ClinConnect Summary

Intracerebral haemorrhage (ICH) is one of the most serious subtypes of stroke, affecting over a million people worldwide each year, most of whom live in Asia. About one third of people with ICH die early after onset and the majority of survivors are left with major long-term disability. Despite the magnitude of the disease burden and cost on healthcare resources, there remains uncertainty about the role of surgery for ICH and no acute medical therapies have been shown to definitely alter outcome in ICH.

The INTERACT2 study follows the recently completed initial pilot study vanguard phase) ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with CT-confirmed spontaneous Intracerebral Haemorrhage (ICH)
• • Elevated systolic blood pressure (\>150mmHg and \<220mmHg)
• • Capacity to commence randomly assigned treatment within 6 hours of onset of ICH.
• • Able to be 'actively' treated and admitted to a monitored facility
• Exclusion Criteria:
• • Clear indication or contraindication to intensive BP lowering.
• • Evidence ICH secondary to a structural abnormality
• • Use of thrombolytic agent
• • Previous ischaemic stroke within 30 days
• • A very high likelihood that the patient will die within the next 24 hours on the basis of clinical and/or radiological criteria
• • Score of 3-5 on the Glasgow Coma Scale (indicating deep coma)
• • Significant pre-stroke disability or advanced dementia
• • Planned early neurological intervention
• • Participation in another clinical trial.
• • A high likelihood that the patient will not adhere to the study treatment and follow-up regimen.